| Document |
Document Title |
|
WO/2014/112280A1 |
Provided are: a low-cost oily composition that is easily prepared, and additionally that has the combination of all of high safety with respect to living bodies and the environment, favorable thickening and gel-forming performance, a sup...
|
|
WO/2014/103998A2 |
The objective of the present invention is to provide a tyrosine derivative which is useful as a melatonin receptor 1 MT1 antagonist, and a method for efficiently manufacturing a specific m-tyrosine derivative in which an iodine atom is i...
|
|
WO/2014/095920A1 |
The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respirato...
|
|
WO/2014/092161A1 |
The present invention addresses the problem of providing a method for producing an industrially-suitable carbamate compound without requiring a complicated operation, wherein a carbamate compound of a quality suitable for producing an is...
|
|
WO/2014/069605A1 |
The present invention relates to a polyisocyanate composition which comprises, based on the total mass of the polyisocyanate composition: 97 weight% or more of a polyisocyanate; 2.0 mass ppm to 1.0×104 mass ppm of a compound which is di...
|
|
WO/2014/066772A1 |
This disclosure relates to processes and reagents for making diaryliodonium salts, which are useful for the preparation of fluorinated, iodinated, astatinated and radiofluorinated aromatic compounds.
|
|
WO/2014/057495A1 |
A commercially viable process for industrial preparation of [(S)-n-tert butoxycarbonyl-3-hydroxy]adamantylglycine which is a key intermediate for saxagliptin synthesis and is represented by compound of Formula-VI. The compound-VI obtaine...
|
|
WO/2014/050426A1 |
The present invention provides a method for producing a liquid crystal composition in a single step, said liquid crystal composition using two or more different types of carboxylic acid as a type of raw material, and having the ability t...
|
|
WO/2014/044873A1 |
There are provided amino acid derivatives of formula V and VI as defined herein which are pyrrolysine analogs for use in bioconjugation processes.
|
|
WO/2014/023270A1 |
A salt or co-crystal of ethyl N-[2-amino-4-[(4-fluorophenyl)methylamino]- phenyl]carbamate and one acid selected from the group consisting of hydrobromic acid, hydrochloric acid, methanesulphonic acid, benzenesulphonic acid, fumaric acid...
|
|
WO/2014/023643A1 |
The invention provides novel multitarget inhibitors of the enzymes Fatty Acid Amide Hydrolase (FAAH), Cyclooxygenase-1 (COX-1) and/or Cyclooxygenase-2 (COX-2) having a specific carbamate moiety on the meta or ortho position of the A ring...
|
|
WO/2014/023325A1 |
The invention provides novel multitarget inhibitors of the enzymes Fatty Acid Amide Hydrolase (FAAH), Cyclooxygenase-1 (COX-1) and/or Cyclooxygenase-2 (COX-2) having a specific carbamate moiety on the meta or ortho position of the A ring...
|
|
WO/2014/021166A1 |
This method for producing a blocked isocyanate compound represented by general formula (III) is characterized in that: a (meth)acryloyl group-containing isocyanate compound represented by general formula (I) and an oxime compound represe...
|
|
WO/2014/018913A2 |
The compositions and methods described herein relate generally to Santacruzamate A compositions and analogs, which, among other features, are useful as histone deacetylase (HDAC) inhibitors.
|
|
WO/2014/014035A1 |
The invention pertains to a novel pyrophosphoric acid ester compound represented by formula (1) and a bisphosphoric acid ester compound represented by formula (2). In the formulas, R is an aryl group, organic silyl group, or halogen atom...
|
|
WO/2014/014606A1 |
A method for treating carbon dioxide includes preparing a polyamine composition and delivering a stream containing carbon dioxide to the polyamine composition. The carbon dioxide reacts with polyamine in the polyamine composition to form...
|
|
WO/2014/011220A2 |
This invention relates to the treatment of androgen receptor-positive breast cancer in a subject, for example a female subject. Accordingly, this invention provides methods of: a) treating a subject suffering from breast cancer; b) treat...
|
|
WO/2014/007398A1 |
Provided are: a cationic lipid represented by formula (A) or the like, which makes it easier to introduce a nucleic acid into, for example, a cell; a composition which contains the cationic lipid and a nucleic acid; a method for introduc...
|
|
WO/2014/003203A2 |
A novel method for producing a stereoselective epoxyketone compound is provided. A method for producing an epoxyketone compound represented by the formula (1), as represented by the following scheme, whereby it is possible to obtain an e...
|
|
WO/2013/191252A1 |
[Problem] To provide: a method for producing a compound having an acryloyl group or methacrylic group, wherein the target acrylic or methacrylic compound is obtained simply and at high purity and favorable yield merely by avoiding a wate...
|
|
WO/2013/187480A1 |
An aim of the present invention is to provide a novel cyclic depsipeptide derivative and a pest control agent comprising the same. According to the present invention, a compound represented by formula (1) or a stereoisomer thereof, a pes...
|
|
WO/2013/185435A1 |
The present invention relates to an optical activity axially chiral α-allenic alcohol, a synthesis method and use thereof. A method of preparing a high optical activity chiral α-allenic alcohol by using propargyl alcohol, aldehyde and ...
|
|
WO/2013/185116A1 |
The description is directed to ionizable lipids useful for enhancing the delivery of therapeutic agents in liposomes.
|
|
WO/2013/180271A1 |
Provided are a fluorine-containing amino acid prodrug represented by general formula (I) that makes a fluorine-containing amino acid which is a group 2 metabotropic glutamate receptor agonist into a prodrug, or a pharmacologically accept...
|
|
WO/2013/173779A1 |
The invention provides new processes for making and purifying amino acid compounds, which are useful in the preparation of AKT inhibitors used in the treatment of diseases such as cancer, including the compound (S)-2-(4-chlorophenyl)-1-(...
|
|
WO/2013/171135A1 |
The invention relates to compounds of the formula (I) to a process for making same and to the use of the products in the solid phase peptide synthesis. The compounds of formula I are versatile peptide intermediates for the solid phase pe...
|
|
WO/2013/172466A1 |
A method for forming a negative pattern includes (i) forming a film from an actinic ray-sensitive or radiation-sensitive resin composition, (ii) exposing the film, and (iii) developing the exposed film by using a developer containing an ...
|
|
WO/2013/165606A1 |
Disclosed are modulators of the human relaxin receptor 1, for example, of formula (I), wherein A, R1, and R2 are as defined herein, that are useful in treating mammalian relaxin receptor 1 mediated facets of human health, e.g., cardiovas...
|
|
WO/2013/165575A1 |
The invention relates to fluorinated compounds and their use as anti-epileptic, muscle- relaxing, fever-reducing and peripherally analgesically acting medications and as imaging agents. Novel fluorinated 2-amino-4-(benzylamino)phenyl car...
|
|
WO/2013/135360A1 |
The present invention is directed to a new class of lipids, more specifically ether-lipids having a polar headgroup, as well as vesicles comprising these lipids, methods of their preparation as well as their uses in medical applications,...
|
|
WO/2013/130849A1 |
This invention relates to novel substituted dioxopiperidinyl phthalimide derivatives and pharmaceutically acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the us...
|
|
WO/2013/126803A1 |
The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel, trialkyl, cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation ...
|
|
WO/2013/120257A1 |
Provided is a method for synthesizing a laevo-p-hydroxyphenylglycine compound, comprising: (1) subjecting an amine compound with a glyoxylic acid ester compound to a nucleophilic addition reaction; subjecting the product obtained in step...
|
|
WO/2013/116715A1 |
Methods and intermediates useful for preparing a compound of formula I and salts thereof.
|
|
WO/2013/114379A1 |
The present invention relates to novel polymorphs of N-[2-amino-4-(4-tluorobenzylamino )-phenyl] carbamic acid ethyl ester, processes for preparing them, and pharmaceutical composition comprising them. In one aspect, the present inventio...
|
|
WO/2013/116174A1 |
The present invention provides novel mGlu2/3 agonists of formula (I) useful in the treatment of neurological or psychiatric disorders.
|
|
WO/2013/114315A1 |
A method for the preparation of retigabine starting with intermediate III is disclosed, comprising the step of protecting the secondary amine of III with a protecting group followed by N-ethoxycarbonylation of the primary amino group of ...
|
|
WO/2013/107405A1 |
Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
|
|
WO/2013/103973A1 |
This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compunds as at le...
|
|
WO/2013/100570A1 |
A phenyl carbamate compound, a pharmaceutical composition for preventing and/or treating epilepsy comprising the phenyl carbamate compound as an active ingredient, and a use of the phenyl carbamate compound for preventing and/or treating...
|
|
WO/2013/100567A1 |
A phenyl carbamate compound; a composition for treating and/or alleviating pain containing the phenyl carbamate compound or a pharmaceutically acceptable salt thereof as an active ingredient; a method of treating and/or alleviating pain ...
|
|
WO/2013/100569A1 |
A phenyl carbamate compound, a pharmaceutical composition for preventing and/or treating multiple sclerosis comprising the phenyl carbamate compound as an active ingredient, and a use of the phenyl carbamate compound for preventing and/o...
|
|
WO/2013/099623A1 |
As represented by formula (1), (1) when hydrolysis reaction of methyl laurate was performed by adding methyl laurate (2 mmol) and water (8 ml) to a pyrosulfuric acid ammonium salt catalyst (5 mol%) and heating the mixture to 60°C for 24...
|
|
WO/2013/100566A1 |
A phenyl alkyl carbamate derivative compound and a pharmaceutical composition containing the compound are provided. More specifically, the phenyl alkyl carbamate derivative compound and a pharmaceutically acceptable salt thereof, a compo...
|
|
WO/2013/100568A1 |
A phenyl carbamate compound; a composition for treating and/or preventing stroke containing the phenyl carbamate compound or a pharmaceutically acceptable salt thereof as an active ingredient; a method of treating and/or preventing strok...
|
|
WO/2013/094390A1 |
A photo-curable composition contains a radicalpolymerizable monomer (A), a photopolymerization initiator (B), and a compound (C) Serving as a sensitizer and having the following general formula(1). X1 and X2 are selected from the group c...
|
|
WO/2013/067679A1 |
A method for preparing polymethylene polyphenyl polyamino formate is provided, which is carried through the condensation of phenylaminoformate with methylating reagent under the catalyzation of phase-transfer acidic catalyst. The method ...
|
|
WO/2013/070118A1 |
This invention relates to novel substituted 4,5-diamino-3-alkyloxy- cyclohex-1-ene carboxylic acids, esters thereof or pharmaceutically acceptable salts and/or hydrates, to novel antiviral medicines - inhibitors of the activity of neuram...
|
|
WO/2013/065825A1 |
Provided is a cationic lipid expressed in the following formula (I), which facilitates introduction of a nucleic acid into a cell, a composition containing the cationic lipid and the nucleic acid, a method for introducing the nucleic aci...
|
|
WO/2013/067163A1 |
In one aspect, the invention relates to compounds having the formula: (I) where R1-R6, a, b, and Z are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. I...
|
